2 results
Approved WMOPending
To evaluate the dose-response relationship of SVT-404776 on efficacy.
Approved WMOCompleted
The primary objective of this phase III study is to demonstrate that lixisenatide can reduce cardiovascularmorbidity and mortality (composite endpoint of cardiovascular (CV) death, non-fatal myocardialinfarction (MI), non-fatal stroke,…